#stcsm search results

Novel research into cancers of the esophagus & stomach is being presented now at #GI26 during a rapid oral abstract session chaired by Dr. Matthew Strickland; Q&A to follow. #esosm #stcsm brnw.ch/21wYWm1 @mcruzcorrea

A great opening session continues at #GI26 with “Oral Abstract Session A: Cancers of the Esophagus & Stomach” co-chaired by Dr. David Wang & Dr. Nathaniel Evans. #esocsm #stcsm brnw.ch/21wYVFa @KoheiShitara @DanielLinMD

10/10 FORTITUDE 101 #STCsm #ESMO25 #plenary ph3 1L FOLFOX +/- bemartizumab in FGFR2b+ advanced G/GEJC N=324 (efficacy) - initial OS benefit observed but attenuated over time - 45% of bema pts with G3+ corneal events ⛔️subsequent press release for FORTITUDE 102 (FOLFOX/nivo

⭐@HyungDonKim86 from @AsanMedicalCtr presents AI model predicting claudin18.2 & immune phenotype, aiding treatment selection (incl. zolbetuximab) in gastric cancer: 🎥 ow.ly/CuaN50X36FE @ASCO #ASCO25 #ImmunoOnc #STCsm This video is available on the GI Cancer Channel on

➡️In GEJ cancer, local recurrence is less the problem → metastases drive mortality. 🎥@YJanjigianMD (@MSKCancerCenter): shift toward systemic periop therapy, thorough staging, & longer treatment to improve cures 🔗 ow.ly/vpnj50WU6Z2 @myESMO #GI25 #STCsm #UroOnc #UroSoMe

ATG-022 Earns Breakthrough Therapy Designation in China for Advanced Gastric/GEJ Adenocarcinoma #GastricCancer #stcsm #GEJcancer onclive.com/view/atg-022-e…

🎥@YJanjigianMD (@MSKCancerCenter) emphasizes multidisciplinary staging & systemic therapy in GE cancer. ⭐With trials like MATTERHORN, focus shifts from local control to tackling mets. Longer periop therapy may boost cure rates: Watch🔗ow.ly/3LUe50WsFqf @myESMO #STCsm

🎥@YJanjigianMD (@MSKCancerCenter) shares updates in gastric & GEJ cancer at #ESMOGI25: periop strategies like MATTERHORN, HER2–PD-1 & FGFR2B targeting, and tackling IO resistance in mGC. Promising advances in a tough space. 🔗 ow.ly/80Tf50WsxVb @myESMO #STCsm #ImmunoOnc

🎥@HyungDonKim86 of @AsanMedicalCtr presents an AI model predicting claudin 18.2 expression & immune phenotypes in gastric cancer. This tool may personalize treatment, identifying who benefits most from ICIs + chemo: ➡️ow.ly/egYO50W4WCK⬅️ @ASCO #ASCO25 #STCsm #ImmunoOnc

🎥@YJanjigianMD of @MSKCancerCenter highlights the Phase III MATTERHORN trial showing improved pCR and EFS with durvalumab + FLOT in resectable gastric/GEJ cancer. 📺 Watch the full insights: ow.ly/3jgj50W4TCO @ASCO #ASCO25 #STCsm #ImmunoOnc #TrialUpdate #CTSM

🎥@KoheiShitara shares DESTINY-Gastric04 results: T-DXd significantly improves OS vs ramucirumab + paclitaxel in 2L HER2+ gastric/GEJ cancer, with a consistent safety profile. 📺 Watch: ow.ly/6Rmr50W4SlH @ASCO #ASCO25 #GastricCancer #STCsm #ImmunoOnc #TrialUpdate #CTSM

#ASCO25 2nd Plenary this year for our patients with gastrointestinal cancers. Chemo 🆚 Chemo➕Immunotherapy Immunotherapy continues to have an impact across solid tumors neoadjuvant⏪️peri-operative⏪️adjuvant. 👇🏽For gastric/gastroesphageal cancer.. @OncoAlert #STCSM

⭐️ DESTINY-Gastric04 💫 Congratulations @KoheiShitara , @YJanjigianMD , all investigators. #ASCO25 @NEJM #gastric #stcsm

Did you know… According to @WHO, gastric cancer is the 5th most common cancer worldwide and the 3rd leading cause of cancer-related deaths. On #WorldDigestiveHealthDay, here’s what you need to know about this often silent but serious disease. #GICancer #stcsm

📢 #OncTwitter, please weigh in #crcsm #stcsm #bcsm #pancsm

At #ASCO24, @sandrapdangelo will present a planned interim analysis of the pivotal IGNYTE-ESO trial that evaluated lete-cel in patients with synovial #sarcoma or myxoid/round cell liposarcoma. @ASCO @MSKCancerCenter #stcsm 💠 11:30 a.m. CT | Hall D2

Best Practices and Practical Nuances in the Treatment of Gastric Cancer in High-Risk Global Areas [Oct 29, 2018] Federico A. Sanchez @licosan11 ow.ly/SPiJ50IGFZO #stcsm #globonc @Aurora_Cancer

Novel research into cancers of the esophagus & stomach is being presented now at #GI26 during a rapid oral abstract session chaired by Dr. Matthew Strickland; Q&A to follow. #esosm #stcsm brnw.ch/21wYWm1 @mcruzcorrea

The Claudin18.2–directed autologous CAR T-cell therapy satri-cel led to a statistically significant improvement in PFS vs physician’s choice of therapy in patients with CLDN18.2-positive advanced gastric/GEJ cancer. #stcsm #Oncology #MedTwitter onclive.com/view/satri-cel…

‼️ #ASCOPlenarySeries: Zolbetuximab + CAPOX improves survival in patients with CLDN18.2+/HER2− LA mG/GEJ adenocarcinoma Tune in to the live presentation, expert discussion and Q&A TODAY @ 4 PM ET ➡️ fal.cn/3wNad @OncoAlert @mdmanishshah @yjanjigianMD #STCSM #ESOCSM

Melanie N. Allard, DNP, APRN, FNP-BC, CCRN — Caring for Patients with GI Cancers — 3/21. learn.unclcn.org/CCO-03212023. #Stcsm #GICancer #GastricCancer #OncologyCare #CommunityCollege #ContinuingEducation #Cancer

A great opening session continues at #GI26 with “Oral Abstract Session A: Cancers of the Esophagus & Stomach” co-chaired by Dr. David Wang & Dr. Nathaniel Evans. #esocsm #stcsm brnw.ch/21wYVFa @KoheiShitara @DanielLinMD

☂️ K-Umbrella #GastricCancer study demonstrated feasibility of standard-of-care, controlled, biomarker-integrated, randomized umbrella trial to assess novel therapies in advanced GC. ➡️ brnw.ch/21wESsH #stcsm #gicsm @choong_kun

🚨 Hereditary #GastricCancer risk reduction with total gastrectomy has life-altering consequences. ➡️ brnw.ch/21wEY0x #stcsm #surgonc #gencsm #gicsm @JeremyLDavisMD

👍 Frontline NIVO + chemotherapy maintains HRQoL with lower deterioration risk in #GastricCancer ➡️ brnw.ch/21wDZR7 #EsophagealAdenocarcinoma #stcsm #esocsm #QOL #ImmunoOnc

#EGFR amplified upper GI adenocarcinomas; an under recognized subset. #GI23 @ASCO preclinical and PDX data being presented. Also shoutout 🗣️to our paper @JCO_ASCO @SteveMaronMD🙌🏾. #STCSM #ESOCSM

🧐 HIPEC after CRS in #GastricCancer w/peritoneal metastasis 👀 No impact on overall survival 📈PFS and MFS were significantly prolonged 🤕 Did not increase surgical complications ➡️ brnw.ch/21wEYqy #stcsm #surgonc #gicsm

⭐️ DESTINY-Gastric04 💫 Congratulations @KoheiShitara , @YJanjigianMD , all investigators. #ASCO25 @NEJM #gastric #stcsm

An honor to meet an inspiring survivor like you @hanscooks and thanks for sharing this amazing resource for #esocsm and #stcsm patients and survivors. Love the multi-D representation here at #ASCO24, especially patient advocates. #GIonc #supponc

#GI23 #ClinicalTrials Switching gears to an agent not available in 🇺🇸. 👇🏾Adjuvant S1 for pathologic stage-2 gastric cancer. #STCSM

Dr Dayyani (@UCI_GI_ONC) and colleagues conduct a Ph2 trial for #stcsm #esocsmpatients combining cabozantinib and pembrolizumab in #IOrefractory patients with 22.2% PFS at 6 months without any new toxicities #GIonc @MayCho_MD @JoeChaoMD doi.org/10.1093/oncolo…

Did you miss yesterday's #ASCOPlenarySeries session highlighting the Phase 3 GLOW results of zolbetuximab + CAPOX in CLDN18.2+/HER2− locally advanced mG/GEJ adenocarcinoma? Catch up here ➡️ fal.cn/3wPG8 @OncoAlert @mdmanishshah @YJanjigianMD #STCSM #ESOCSM

Fellow #Hoosier transplant Dr @ashiq_masood presents the current standard of care in #esocsm and #stcsm and the challenges of high % of recurrence, low pCR rates and quick exhaustion of therapy options #GI24 #GIonc

Dr @rutikamehtaMD & colleagues discuss #FGFR2 as a target in #stcsm #esocsm. @GuardantHealth ctDNA analysis shows #FGFR2amp in <4% of cases. They postulate that #FGFR2inhibitors in trials may improve outcomes #GIonc @UCI_GI_ONC @KlempnerSam doi.org/10.1093/oncolo…

SIGX1094 won a fast track designation by the @US_FDA for use in patients with diffuse gastric cancer. #stcsm #FDA hubs.li/Q03cmyLG0